glp-1 sarcopenia Glucagon‐like peptide‐1 receptor agonists and muscle strength changes in older adults: Risks beyond muscle mass reductions - Prokopidis - British Journal of Pharmacology Glucagon Like Peptide-1 Receptor Agonists

After four weeks, the dose typically increases to 0.5mg per week for another four weeks, then continues titrating upward

The FDAs current safety page continues to cite concerns about immunogenicity, peptide impurities and limited safety data, and the agency has stated that a substance may still pose significant safety risks

The underlying biology of the intervertebral disc is similar throughout the spine

Patients should be counseled on strategies to minimize these effects, including eating smaller meals, avoiding high-fat foods, and maintaining adequate hydration

Acosta A, Camilleri M

Although numerous experimental studies, primarily in animal models, have demonstrated the beneficial effects of GLP-1 agonists (e.g., liraglutide and exenatide) in sepsis, including reduced inflammation, improved organ function, and prolonged survival, their clinical use in humans is not yet routine and remains under investigation